Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia

Published:2021-06 Issue:9 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Si Lim Stephanie J.¹²³⁴^ORCID,Grupp Stephen A.¹²,DiNofia Amanda M.¹²

Affiliation:

1. Department of Pediatrics University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

2. Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

3. Division of Pediatric Oncology‐Hematology, University of Hawai'i Cancer Center Kapi'olani Medical Center for Women and Children Honolulu Hawaii USA

4. Department of Pediatrics University of Hawai'i School of Medicine Honolulu Hawaii USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29123

Reference82 articles.

1. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

2. FDA.FDA Approves Tisagenlecleucel for B‐cell ALL and Tocilizumab for Cytokine Release Syndrome.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed September 26 2020.

3. Novartis.Kymriah (Tisagenlecleucel) the First‐in‐Class CAR‐T Therapy from Novartis Receives Second FDA Approval to Treat Appropriate r/r Patients with Large B‐Cell Lymphoma.https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma. Accessed July 18 2020.

4. Childhood and adolescent cancer statistics, 2014

5. Acute Lymphoblastic Leukemia in Children

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials;Trends in Biotechnology;2024-08

2. Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies;American Society of Clinical Oncology Educational Book;2024-06

3. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics;Journal of Translational Medicine;2024-05-21

4. Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors;MedComm – Future Medicine;2024-05-13

5. Challenges and strategies associated with CAR-T cell therapy in blood malignancies;Experimental Hematology & Oncology;2024-02-24